While MCT1 inhibition with AZD3965 is demonstrated to increase glycolytic intermediate levels and enzyme activity, causing intracellular lactate accumulation [83], a recent study in human breast cancer cells contradicts this, indicating that AZD3965 does not influence glycolytic activity or intracellular lactate accumulation [40]. This evidence concerns the gene SLC16A1 and breast cancer.